{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:06:47Z","timestamp":1787238407160,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"DOI":"10.1215\/s1152851704000183","type":"journal-article","created":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T18:08:39Z","timestamp":1112206119000},"page":"177-182","source":"Crossref","is-referenced-by-count":70,"title":["Oral sodium phenylbutyrate in patients with recurrent malignant gliomas:\nA dose escalation and pharmacologic study"],"prefix":"10.1093","volume":"7","author":[{"given":"Surasak","family":"Phuphanich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,4,1]]},"reference":[{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Baker, M.J., Brem, S., Daniels, S., Sherman, B., and Phuphanich, S.\n(2002) Complete response of a recurrent, multicentric malignant\nglioma in a patient treated with phenylbutyrate. J.\nNeurooncol.59,239\n-242.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Batchelor, T.T., Gilbert, M.R., Supko, J.G., Carson, K.A., Nabors,\nL.B., Grossman, S.A., Lesser, G.J., Mikkelsen, T., and Phuphanich, S.\n(2004) Phase 2 study of weekly irinotecan in adults with\nrecurrent malignant glioma: Final report of NABTT 97-11.\nNeuro-Oncol.6,21\n-27","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Buckner, J.C., Malkin, M.G., Reed, E., Cascino, T.L., Reid, J.M.,\nAmes, M.M., Tong, W.P., Lim, S., and Figg, W.D. (1999) Phase II\nstudy of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients\nwith recurrent glioma. Mayo Clin. Proc.74,137\n-145.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Carducci, M.A., Nelson, J.B., Chan-Tack, K.M., Ayyagari, S.R.,\nSweatt, W.H., Campbell, P.A., Nelson, W.G., and Simons, J.W.\n(1996) Phenylbutyrate induces apoptosis in human prostate cancer\nand is more potent than phenylacetate. Clin. Cancer\nRes.2,379\n-387.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Carducci, M.A., Gilbert, J., Bowling, M.K., Noe, D., Eisenberger,\nM.A., Sinibaldi, V., Zabelina, Y., Chen, T.L., Grochow, L.B., and Donehower,\nR.C. (2001) A phase I clinical and pharmacological evaluation of\nsodium phenylbutyrate on a 120-h infusion schedule. Clin. Cancer\nRes.7,3047\n-3055.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Spence, A.M.,\nBerger, M.S., Mehta, M.P., Bozik, M.E., Pollack, I., Schiff, D., Gilbert, M.,\nRankin, C., and Prados, M.D. (1999) Phase II study of\nphenylacetate in patients with recurrent malignant glioma: A North American\nBrain Tumor Consortium report. J. Clin. Oncol.17,984\n-990.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Dmitrovsky, E., Markman, M., and Marks, P.A. (1990)\nClinical use of differentiating agents in cancer therapy. Cancer\nChemother. Biol. Response Modif.11,303\n-320.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Fetell, M.R., Grossman, S.A., Fisher, J.D., Erlanger, B., Rowinsky,\nE., Stockel, J., and Piantadosi, S. (1997) Preirradiation\npaclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug\ninteractions. New Approaches to Brain Tumor Therapy Central Nervous System\nConsortium. J. Clin. Oncol.15,3121\n-3128.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Gibaldi, M., and Perrier, D. (1982) Noncompartmental\nanalysis based on statistical moment theory. Chapter 11 in\nPharmacokinetics. New York: Marcel Dekker. pp.409\n-417.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Gilbert, J., Baker, S.D., Bowling, M.K., Grochow, L., Figg, W.D.,\nZabelina, Y., Donehower, R.C., and Carducci, M.A. (2001) A phase\nI dose escalation and bioavailability study of oral sodium phenylbutyrate in\npatients with refractory solid tumor malignancies. Clin. Cancer\nRes.7,2292\n-2300.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Gilbert, M.R., Supko, J.G., Batchelor, T., Lessor, G., Fisher,\nJ.D., Piantadosi, S., and Grossman, S.A. (2003) Phase I clinical\nand pharmacokinetic study of irinotecan in adults with recurrent glioma.\nClin. Cancer Res.9,2940\n-2949.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Gore, S.D., Samid, D., and Weng, L.J. (1997a) Impact\nof the putative differentiating agents sodium phenylbutyrate and sodium\nphenylacetate on proliferation, differentiation, and apoptosis of primary\nneoplastic myeloid cells. Clin. Cancer Res.3,1755\n-1762.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Gore, S.D., Miller, C.B., Weng, L.J., Burks, K., Griffin, C.A.,\nChen, T.-L., Smith, V., Burke, P.J., Grever, M., and Rowinsky, E.K.\n(1997b) Clinical development of sodium phenylbutyrate as a\nputative differentiating agent in myeloid malignancies. Anticancer\nRes.17,3938\n (abstract 29).","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Gore, S.D., Weng, L.J., Figg, W.D., Zhai, S. Donehower, R.C.,\nDover, G., Grever, M.R., Griffin, C., Grochow, L.B., Hawkins, A., Burks, K.,\nZabelena, Y., and Miller, C.B. (2002) Impact of prolonged\ninfusions of the putative differentiating agent sodium phenylbutyrate on\nmyelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer\nRes.8,963\n-970.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Grossman, S.A., Fisher, J.D., Piantadosi, S., and Brem, H.\n(1998a) The New Approaches to Brain Tumor Therapy (NABTT) CNS\nConsortium: Organization, objectives, and activities. Cancer\nControl5,107\n-114.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Grossman, S.A., Hochberg, F., Fisher, J., Chen, T.L., Kim, L.,\nGregory, R., Grochow, L.B., and Piantadosi, S. (1998b) Increased\n9-aminocamptothecin dose requirements in patients on anticonvulsants.\nCancer Chemother. Pharmacol.42,118\n-126.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Hudgins, W.R., Pineau, T., Sher, T., Gonzales, F.J., Myers, C.E.,\nand Samid, D. (1994) Anticancer activity of phenylacetate and\nrelated aromatic fatty acids: Correlation with lipophilicity and capacity to\nactivate nuclear receptor. Proc. Am. Assoc. Can. Res.35, 391 (abstract\n2332).","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Kaplan, E.L., and Meier, P. (1958) Nonparametric\nestimation from incomplete observations. J. Am. Stat.\nAssoc.53,457\n-481.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Samid, D., Shack, S., and Myers, C.E. (1993) Selective\ngrowth arrest and phenotypic reversion of prostate cancer cells in vitro by\nnontoxic pharmacological concentrations of phenylacetate. J. Clin.\nInvest.91,2288\n-2295.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Samid, D., Ram, Z., Hudgins, W.R., Shack, S., Liu, L., Walbridge,\nS., Oldfield, E.H., and Myers, C.E. (1994) Selective activity of\nphenylacetate against malignant gliomas: Resemblance to fetal brain damage in\nphenylketonuria. Cancer Res.54,891\n-895.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Sidell, N., Wada, R., Han, G., Chang, B., Shack, S., Moore, T., and\nSamid, D. (1995) Phenylacetate synergizes with retinoic acid in\ninducing the differentiation of human neuroblastoma cells. Int. J.\nCancer60,507\n-514.","DOI":"10.1002\/ijc.2910600414"},{"key":"key\n\t\t\t\t20171012053610_","doi-asserted-by":"crossref","unstructured":"Warrell, R.P., Jr., He, L.Z., Richon, V., Calleja, E., and\nPandolfi, P.P. (1998) Therapeutic targeting of transcription in\nacute promyelocytic leukemia by use of an inhibitor of histone deacetylase.\nJ. Natl. Cancer Inst.90,1621\n-1625.a","DOI":"10.1002\/ijc.2910600414"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/7\/2\/177\/13066102\/NO007-02_07Phuphanich.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T05:36:55Z","timestamp":1507786615000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article\/7\/2\/177\/1000505\/Oral-sodium-phenylbutyrate-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,4,1]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1215\/s1152851704000183","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,4]]},"published":{"date-parts":[[2005,4,1]]}}}